NeuropaceNPCE
About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Employees: 184
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2,500% more call options, than puts
Call options by funds: $260K | Put options by funds: $10K
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
126% more capital invested
Capital invested by funds: $103M [Q3] → $234M (+$130M) [Q4]
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
29% more funds holding
Funds holding: 48 [Q3] → 62 (+14) [Q4]
19.24% more ownership
Funds ownership: 50.67% [Q3] → 69.91% (+19.24%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Cantor Fitzgerald Ross Osborn 20% 1-year accuracy 9 / 45 met price target | 83%upside $20 | Overweight Maintained | 5 Mar 2025 |
Wells Fargo Larry Biegelsen 22% 1-year accuracy 10 / 46 met price target | 56%upside $17 | Overweight Maintained | 30 Jan 2025 |
Financial journalist opinion
Based on 5 articles about NPCE published over the past 30 days









